Abstract:Objective: To observe the clinical efficacy of transcatheter arterial chemoembolization (TACE) in combination with injection of arsenic trioxide on the primary hepatocarcinoma. Methods: We selected a total of 156 patients with primary hepatic carcinoma that were not available to perform surgical resection and received treatment in this hospital between January and December in 2017. According to the treatment strategy, patients were divided into two groups, i.e. the observation group and the control group, with 78 in each group. In the observation group, patients received one cycle of intravenous injection of 10 mg arsenic trioxide dissolved in 500 mL normal saline for consecutive 7 days, followed by 10 days of recovery, and treatment lasted for 4 cycles; additionally, TACE treatment was performed with 40 mg epirubicin and 10 mL ultra-fluid lipiodol, i.e. after emulsification, drugs were delivered into the vessels that.supplied blood surrounding the tumors; one cycle of TACE treatment consisted of 4 to 8 weeks. In the control group, patients only underwent TACE treatment that was same as the observation group. After 3 cycles of TACE, we evaluated the efficacy, survival rates, life quality and adverse reactions at 0.5, 1 and 2 years. Results: The effective rates in the observation group and the control group were 70.51% (55/78) and 57.69% (45/78), respectively, and the difference between two groups showed statistical significance (p<0.05). Between the observation group and the control group, comparisons of the median of survival (837 vs. 8.12 months), average of survival (12.97 vs. 8.79 months) and survival rate at 0.5 year (88.46% vs. 83.33%) showed no statistically significant difference (p>0.05). However, one- and two-year survival rates in the observation group were significantly higher than those in the control group (one-year survival rate: 62.82% vs. 44.87%; two-year survival rate: 26.92% vs. 17.95%; p<0.05).The improvement rate in the observation group was 76.92%, also significantly higher than 55.12% in the control group (p<0.05). Adverse reactions, including increases in glutamic oxalacetic transaminase and glutamic-pyruvic transatninase, decreases in albumin, and anomaly in bilirubin and echocardiography, were seen in two groups, and the differences had statistical significance (p<0.05). Conclusion: TACE in combination with intravenous injection of arsenic trioxide gains promising efficacy on primary hepatic carcinoma, which can improve the survival and life quality of patients, and ameliorate the adverse reactions of treatment. Thus, it has a critical value in clinical practice.

Clinical Observation on TACE Combined with Intraperitoneal Hyperthermic Chemoperfusion for Primary Hepatic Carcinoma

Evaluation of the Efficacy for Alternated Treatment on Primary Liver Cancer by Interventional Therapy in Combination with Fractionated Stereotactic Conformal Radiotherapy

Evaluation of the Curative Effect of Transcatheter Arterial Chemoembolization Via Hepatic Artery Combined with Percutaneous Ethanol Injection for the Treatment of Primary Hepatocellular Carcinoma

TACE Combined with Thermotherapy for Primary Hepatic Carcinoma; A Meta-Analvsis

A Clinical Observation of Intra—arterial Chenotherapy Combined with Thermotherapy for Prinary Liver Cancer after TACE

Clinical Observation of the Union Treatment of Hepatic Transcatheter Arterial Chemoembolization and Percutaneous Microwave Coagulation Therapy for Hepatic Cellular Carcinoma

Therapeutic Effect of TACE Combined with Compound Sophora Flavescens Injection in Mid and Advanced Stage Primary Liver Cancer

CLINICAL RESEARCH ON THE EFFICACY OF TACE IN COMBINATION WITH INJECTION OF ARSENIC TRIOXIDE ON PRIMARY HEPATOCARCINOMA

A Clinical Study of Transcatheter Arterial Chemoembolization Combined with Three-dimensional Conformal Radiotherapy in Primary Hepatocellular Carcinoma

Clinical Investigation of Chemoembolization of Hepatic Artery Combined with Portal Venous in Treating the Moderate and Advanced Hepatic Carcinomas

Effectiveness and Safety of TACE Combined with AHCS for Primary Hepatic Carcinomas: A Systematic Review

Observation of Hepatic artery Embolism Chemotherapy Combined with Microwaveablation Treatment of huge Hepatocellular Carcinoma

Therapeutic Effects of Transcatheter Arterial Chemoembolization Combined with Gamma-Knife Radiotherapy on Primary Hepatic Carcinoma

Clinical study on microwave ablation combined with transcatheter arterial chemoembolization in treating 46 cases of primary hepatocellular carcinoma

TACE Combined with HIFU for Primary Hepatic Carcinomas:A Meta-Analysis

Clinical Efficacy of Transcatheter Arterial Chemoembolization Combined With Percutaneous Microwave Coagulation Therapy for Advanced Hepatocellular Carcinoma

Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma

Clinical observation of TACE combined with PEI for unresectable hepatocellular carcinoma

The observation of curative effects of intraperitoeal perfusion chemotherapy combined with hypre therm ia ina dvanced abdominal cancerw itha cs ites

Combined PMCT and TACE in the Therapy of Hepatocellular Carcinoma

Evaluation of TACE combined with gamma-knife radiotherapy for primary hepatocellular carcinoma